{"title":"对精神病学渠道的分析。","authors":"Jeffrey Ventimiglia, Amir H Kalali","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In this article, we explore the current state of the psychiatry drug development pipeline. Analysis suggests that overall, the psychiatry pipeline is heavily skewed toward a few major indications and tends to have more programs in early development (Phase I and II) than later stages (Phase III). A review of development sponsors shows a fairly even split of programs between Top 50 Pharmaceutical companies and small to mid-sized biopharmaceutical companies.</p>","PeriodicalId":20822,"journal":{"name":"Psychiatry (Edgmont (Pa. : Township))","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952641/pdf/PE_7_9_14.pdf","citationCount":"0","resultStr":"{\"title\":\"An analysis of the psychiatric pipeline.\",\"authors\":\"Jeffrey Ventimiglia, Amir H Kalali\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this article, we explore the current state of the psychiatry drug development pipeline. Analysis suggests that overall, the psychiatry pipeline is heavily skewed toward a few major indications and tends to have more programs in early development (Phase I and II) than later stages (Phase III). A review of development sponsors shows a fairly even split of programs between Top 50 Pharmaceutical companies and small to mid-sized biopharmaceutical companies.</p>\",\"PeriodicalId\":20822,\"journal\":{\"name\":\"Psychiatry (Edgmont (Pa. : Township))\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952641/pdf/PE_7_9_14.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychiatry (Edgmont (Pa. : Township))\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatry (Edgmont (Pa. : Township))","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
In this article, we explore the current state of the psychiatry drug development pipeline. Analysis suggests that overall, the psychiatry pipeline is heavily skewed toward a few major indications and tends to have more programs in early development (Phase I and II) than later stages (Phase III). A review of development sponsors shows a fairly even split of programs between Top 50 Pharmaceutical companies and small to mid-sized biopharmaceutical companies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
